Cyxone AB (Sweden) Today
Cyxone AB is selling for under 0.018 as of the 1st of February 2025; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 0.018. The performance scores are derived for the period starting the 5th of August 2024 and ending today, the 1st of February 2025. Click here to learn more.
Valuation
Check how we calculate scores
Cyxone Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cyxone AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cyxone AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Ola Skanung |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Cyxone AB (CYXO) is traded on Stockholm Exchange in Sweden and employs 8 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cyxone AB's market, we take the total number of its shares issued and multiply it by Cyxone AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cyxone AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 98.44 M outstanding shares.
Cyxone AB has accumulated about 56.34 M in cash with (43.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cyxone AB Probability Of Bankruptcy
Cyxone AB Risk Profiles
Although Cyxone AB's alpha and beta are two of the key measurements used to evaluate Cyxone AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 6.61 | |||
| Standard Deviation | 13.93 | |||
| Variance | 194.01 | |||
| Risk Adjusted Performance | (0.01) |
Cyxone Stock Against Markets
| CYXO | 0.00 |
|
| Competition | Refresh |
Cyxone AB Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyxone AB stock to make a market-neutral strategy. Peer analysis of Cyxone AB could also be used in its relative valuation, which is a method of valuing Cyxone AB by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.